The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process
Abstract
Epithelial-mesenchymal transition (EMT) is a critical process in the development of many tissues and organs in multicellular organisms that its important role in the pathogenesis of metastasis and tumor cell migration has been firmly established. Decreased adhesive capacity, cytoskeletal reorganization, and increased mobility are hallmarks of the EMT. Several molecular mechanisms promote EMT, Including regulation of the levels of specific cell-surface proteins, ECM-degrading enzymes, and altering the expression of certain transcription factors and microRNAs. EMT process is modulated through multiple signaling pathways including the AKT/mTOR pathway. AKT is a key component in numerous processes which was recently shown to regulate the EMT through suppression of the expression of E-cadherin via EMT transcription factors. On the other hand, mTOR complexes can also regulate the EMT through the regulation of cell's actin cytoskeleton by altering the PKC phosphorylation state and direct phosphorylation and activation of Akt. Here we review the effect of AKT and mTOR on EMT and consequently metastasis and cell motility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Matrix metalloproteinases and tumor metastasis
Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Bolós, V., Peinado, H., Pérez-Moreno, M. A., Fraga, M. F., Esteller, M., & Cano, A. (2003) · Journal of Cell Science · doi:10.1242/jcs.00224 · Cited by 1,100
A Brief Review on the Mechanisms of miRNA Regulation
Cai, Y., Yu, X., Hu, S., & Yu, J. (2009) · Genomics, Proteomics & Bioinformatics · doi:10.1016/s1672-0229(08)60044-3 · Cited by 1,001
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., & Leal, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293659 · Cited by 887
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208429 · Cited by 808
EGF receptor trafficking: consequences for signaling and cancer
Tomas, A., Futter, C. E., & Eden, E. R. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.11.002 · Cited by 779
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., & Nakshatri, H. (2007) · Oncogene · doi:10.1038/sj.onc.1209808 · Cited by 596
Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., Lee, E. Y., Weiss, H. L., O'Connor, K. L., Gao, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4058 · Cited by 543
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition
Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., Dargemont, C., de Herreros, A. G., Bellacosa, A., & Larue, L. (2007) · Oncogene · doi:10.1038/sj.onc.1210546 · Cited by 476
Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer
Vesuna, F., van Diest, P., Chen, J. H., & Raman, V. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.151 · Cited by 362
Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 311
Zuo, J., Zhu, W., Li, M., Li, X., Yi, H., Zeng, G., Wan, X., He, Q., Li, J., Qu, J., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23175 · Cited by 258
Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development
Orlichenko, L. S., & Radisky, D. C. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9143-9 · Cited by 234
Zheng, G., Lyons, J. G., Tan, T. K., Wang, Y., Hsu, T.-T., Min, D., Succar, L., Rangan, G. K., Hu, M., Henderson, B. R., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080983 · Cited by 230
Fenouille, N., Tichet, M., Dufies, M., Pottier, A., Mogha, A., Soo, J. K., Rocchi, S., Mallavialle, A., Galibert, M.-D., Khammari, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040378 · Cited by 230
Visciano, C., Liotti, F., Prevete, N., Cali', G., Franco, R., Collina, F., de Paulis, A., Marone, G., Santoro, M., & Melillo, R. M. (2015) · Oncogene · doi:10.1038/onc.2014.441 · Cited by 214
Gauthier, M. L., Berman, H. K., Miller, C., Kozakeiwicz, K., Chew, K., Moore, D., Rabban, J., Chen, Y. Y., Kerlikowske, K., & Tlsty, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.017 · Cited by 214
Bao, L., Yan, Y., Xu, C., Ji, W., Shen, S., Xu, G., Zeng, Y., Sun, B., Qian, H., Chen, L., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.007 · Cited by 183
Wang, H., Wu, Q., Liu, Z., Luo, X., Fan, Y., Liu, Y., Zhang, Y., Hua, S., Fu, Q., Zhao, M., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.122 · Cited by 182
Jiao, D., Wang, J., Lu, W., Tang, X., Chen, J., Mou, H., & Chen, Q.-Y. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.18 · Cited by 175
Hong, K., Kim, J. H., Hong, J., Yoon, H., Lee, J., Hong, S., & Hong, S. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-28 · Cited by 159
Arima, Y., Inoue, Y., Shibata, T., Hayashi, H., Nagano, O., Saya, H., & Taya, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5680 · Cited by 153
Lee, Y. J., & Han, H. J. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00475.2009 · Cited by 152
Kang, M. H., Kim, J. S., Seo, J. E., Oh, S. C., & Yoo, Y. A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.10.010 · Cited by 151
Serrano, I., McDonald, P. C., Lock, F. E., & Dedhar, S. (2012) · Oncogene · doi:10.1038/onc.2012.30 · Cited by 146
Hao, L., Ha, J. R., Kuzel, P., Garcia, E., & Persad, S. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10824.x · Cited by 146
Gao, Y., Guan, Z., Chen, J., Xie, H., YANG, Z., Fan, J., Wang, X., & Li, L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3041 · Cited by 136
Kim, J., Kong, J., Chang, H., Kim, H., & Kim, A. (2016) · Oncotarget · doi:10.18632/oncotarget.13116 · Cited by 136
Lau, M.-T., & Leung, P. C. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.016 · Cited by 134
miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma
Tao, Z., Wan, J.-L., Zeng, L., Xie, L., Sun, H., Qin, L., Wang, L., Zhou, J., Ren, Z., Li, Y., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20120153 · Cited by 120
MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through PTEN-Mediated PI3K/AKT Pathway
Ke, T., Wei, P., Yeh, K.-T., Chen, W. T., & Cheng, Y. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4305-2 · Cited by 116
Lau, M.-T., So, W., & Leung, P. C. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059083 · Cited by 116
Loss of cell anchorage triggers apoptosis (anoikis) in primary mouse hepatocytes
Smets, F. N., Chen, Y., Wang, L., & Soriano, H. E. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00004-5 · Cited by 109
Duan, W., Rangnekar, V. M., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722312.x · Cited by 99
TGF-β1 functional polymorphisms: a review
Cebinelli, G. C. M., Trugilo, K. P., Badaro‐Garcia, S., & de Oliveira, K. B. (2016) · European Cytokine Network · doi:10.1684/ecn.2016.0382 · Cited by 95
AKT-ions with a TWIST between EMT and MET
Tang, H., Massi, D., Hemmings, B. A., Mandalà, M., Hu, Z., WICKI, A. N., & Xue, G. (2016) · Oncotarget · doi:10.18632/oncotarget.11232 · Cited by 94
Zong, H., Yin, B., Zhou, H., Cai, D., Ma, B., & Xiang, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3321-4 · Cited by 75
Liu, X., Zhang, X., Meng, J., Zhang, H.-F., Zhao, Y., Li, C., Sun, Y., Mei, Q., Zhang, F., & Zhang, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17346 · Cited by 65
mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer
Chen, X., Cheng, H., Pan, T., Liu, Y., Yang, S., Ren, C., Huang, D., Zha, X., & Liang, C. Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22177 · Cited by 57
MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling
Chang, R., Xu, J., Fang, F., Yang, H., & Yang, L. (2016) · Tumor Biology · doi:10.1007/s13277-016-4919-z · Cited by 57
Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion
Oh (2009) · Oncology Reports · doi:10.3892/or_00000467 · Cited by 53
Soltani, A., Bahreyni, A., Boroumand, N., Roshan, M. K., Khazaei, M., Ryzhikov, M., Soleimanpour, S., Avan, A., & Hassanian, S. M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26276 · Cited by 53
Self-citationPhosphorylation of Akt at the C-terminal tail triggers Akt Activation
Liu, P., Wang, Z., & Wei, W. (2014) · Cell Cycle · doi:10.4161/cc.29584 · Cited by 49
Jeevan, D. S., Cooper, J., Braun, A., Murali, R., & Jhanwar‐Uniyal, M. (2016) · PubMed · Cited by 46
Wei, S., Wang, L., Zhang, L., Li, B., Li, Z., Zhang, Q., Wang, J., Chen, L., Sun, G., Li, Q., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5239-z · Cited by 46
Cheng, K., & Hao, M. (2017) · Medical Science Monitor · doi:10.12659/msm.901542 · Cited by 39
MicroRNA-92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway
Zhu, K., Zhang, H., Cao, H., & Xu, D. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105470 · Cited by 38
Huang, H., Huang, W., Lin, C., Chiang, Y., Huang, H.-Y., & Kuo, K. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.07.020 · Cited by 32
Zhang, K., Zhang, M., Zhao, H., Yan, B., Zhang, D., & Liang, J. (2012) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2012.01323.x · Cited by 25
Kwasnicki, A. M., Jeevan, D. S., Braun, A., Murali, R., & Jhanwar‐Uniyal, M. (2015) · PubMed · Cited by 21
Cited by
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Xu, F., Na, L., Li, Y., & Chen, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00416-0 · Cited by 539
RetractedEMT, cancer stem cells and autophagy; The three main axes of metastasis
Babaei, G., Aziz, S. G.-G., & Jaghi, N. Z. Z. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110909 · Cited by 506
Linking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
Ho, K. K. Y., Srivastava, S., Kinnunen, P. C., Garikipati, K., Luker, G. D., & Luker, K. E. (2023) · Bioengineering · doi:10.3390/bioengineering10020269 · Cited by 8
Metadata
- Authors
- Karimi Roshan, M., Soltani, A., Soleimani, A., Rezaie Kahkhaie, K., Afshari, A. R., & Soukhtanloo, M.
- Venue
- Biochimie
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 165
- Pages
- 229-234
- ISSN
- 0037-9042 (ISSN-L)
- 0300-9084
- OpenAlex
- W2967026559
- Cited by
- 254
- References
- 67
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.